Scandion Oncology A/S Cash Flow-to-Debt Ratio
Scandion Oncology A/S cash flow-to-debt ratio. Scandion Oncology A/S (SCOL) has a Cash Flow-to-Debt Ratio of -0.18x as of December 2024, meaning its operating cash flow of Skr-1.82 Million could theoretically repay 0% of its total liabilities (Skr10.01 Million) in one year. See SCOL free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Scandion Oncology A/S (2017–2024)
Cash flow-to-debt ratio of Scandion Oncology A/S from 2017 to 2024. Historical debt coverage capacity for Scandion Oncology A/S across 8 annual periods. Check cash flow reinvestment rate of Scandion Oncology A/S to assess the company's total reinvestment commitment from operating cash flow.
Scandion Oncology A/S Cash Flow-to-Debt Ratio by Year (2017–2024)
Scandion Oncology A/S cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Scandion Oncology A/S. For the full cash flow conversion analysis, see SCOL cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.75x | Skr-27.52 Million | Skr10.01 Million | ▲ +81.3% |
| 2023 | -14.74x | Skr-50.67 Million | Skr3.44 Million | ▼ -304.8% |
| 2022 | -3.64x | Skr-69.44 Million | Skr19.07 Million | ▲ +14.6% |
| 2021 | -4.26x | Skr-49.80 Million | Skr11.68 Million | ▼ -646.3% |
| 2020 | -0.57x | Skr-17.45 Million | Skr30.54 Million | ▲ +91.0% |
| 2019 | -6.36x | Skr-9.96 Million | Skr1.56 Million | ▲ +52.4% |
| 2018 | -13.37x | Skr-13.28 Million | Skr992.64K | ▼ -472.0% |
| 2017 | -2.34x | Skr-1.19 Million | Skr509.02K | — |